Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression

D CilloniE GottardiM FavaUsefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detectionBlood102773774200310.1182/blood-2003-03-098012835231

KM CallT GlaserCY ItoIsolation and characterization of a zinc finger polypeptide gene at the human chromosome-11 Wilms’ tumor locusCell6050952019902154335

V ScharnhorstAJ van der EbAG JochemsenWT1 proteins: functions in growth and differentiationGene273141161200110.1016/S0378-1119(01)00593-511595161

AL MenkeA SchedlWT1 and glomerular functionSemin Cell Dev Biol14233240200310.1016/S1084-9521(03)00026-014627122

GB SilbersteinHK VanP StricklandCT Roberts JrCW DanielAltered expression of the WT1 Wilms tumor suppressor gene in human breast cancerProc Natl Acad Sci USA9481328137199710.1073/pnas.94.15.81329223327

A MakrigiannakisK AminG CoukosJL TillyC CoutifarisRegulated expression and potential roles of p53 and Wilms’ tumor suppressor gene (WT1) during follicular development in the human ovaryJ Clin Endocrinol Metab854494592000

S NakatsukaY OjiT HoriuchiImmunohistochemical detection of WT1 protein in a variety of cancer cellsMod Pathol19804814200616547468

H MiwaM BeranGF SaundersExpression of the Wilms-Tumor Gene (Wt1) in human leukemiasLeukemia640540919921317488

HD MenssenHJ RenklU RodeckPresence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemiasLeukemia9106010671995

K InoueH OgawaT YamagamiLong-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levelsBlood882267227819968822948

H SugiyamaWilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemiaLeuk Lymphoma30556119989669676

J TrkaM KalinovaO HrusakReal-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometryLeukemia1613811389200210.1038/sj.leu.240251212094264

H OgawaH TamakiK IkegameThe usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemiaBlood10116981704200310.1182/blood-2002-06-183112406915

M GargH MooreK TobalJAL YinPrognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemiaBr J Haematol1234959200310.1046/j.1365-2141.2003.04552.x

M OstergaardLH OlesenH HasleE KjeldsenP HoklandWT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre studyBr J Haematol125590600200415147374

M WeisserW KernS RauhutC SchochW HiddemannT HaferlachS SchnittgerPrognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemiaLeukemia1914161423200510.1038/sj.leu.240380915920493

D CilloniE GottardiD De MicheliQuantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patientsLeukemia1621152121200210.1038/sj.leu.240267512357365

D OsborneL FrostK TobalJAL YinElevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemiaBone Marrow Transplant366770200510.1038/sj.bmt.170499215908982

A CandoniM TiribelliE ToffolettiQuantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemiaEur J Haematol826168200910.1111/j.1600-0609.2008.01158.x

D CilloniF MessaF ArrugaEarly prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapyHaematologica93921924200810.3324/haematol.12165

HB OmmenCG NyvoldK BraendstrupRelapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervalsBr J Haematol141782791200810.1111/j.1365-2141.2008.07132.x

Y SakamotoY MariyaS SasakiWT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemiaTohoku J Exp Med219169176200910.1620/tjem.219.16919776535

P ChomczynskiN SacchiSingle-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extractionAnal Biochem162156159198710.1016/0003-2697(87)90021-22440339

J PolákJ MarkovaJ SchwarzJ MaaloufovaZ VolkovaJ CermakC Haskovec[The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients]Cas Lek Cesk14536422006

KA KreuzerA SaborowskiJ LupbergerC AppeltIK NaP Le CoutreCA SchmidtFluorescent 5′-exonuclease assay for the absolute quantification of Wilms’ tumour gene (WT1) mRNA: implications for monitoring human leukaemiasBr J Haematol1143133182001

D CilloniA RennevilleF HermitteReal-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet studyJ Clin Oncol2751955201200910.1200/JCO.2009.22.4865

G GianfaldoniF MannelliV PonzianiG LongoS BenciniA BosiAM VannucchiEarly reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemiaHaematologica95833836201010.3324/haematol.2009.011908